Radiotherapeutic Efficacy of 177Lu-AMBA: Summary of WHO and RECIST Criteria
| Control | Treated | |||
|---|---|---|---|---|
| Criterion | Single dose | 2 dose | Single dose | 2 dose |
| Complete response (%) | 0 | 0 | 31 | 39 |
| Partial response (%) | 0 | 0 | 44 | 61 |
| Stable disease (%) | 0 | 0 | 3 | 0 |
| Progressive disease (%) | 100 | 100 | 22 | 0 |
| Median survival (d) | 49 | 48 | 84 | 114 |
| Time to progression/ progression-free survival (d) | 19 | 15 | 37 | 61 |
Criteria applied to survival and histology data from 177Lu-AMBA radiotherapeutic efficacy studies in PC-3 tumor-bearing Tac:Cr:(NCr)-Foxn1nu homozygous male nude mice: single dose, 27.75 MBq (n = 32); 2 dose, 55.5 MBq (n = 36). Control: single dose, n = 15; 2 dose, n = 16.